How and When to Consider DBS in the Older Patient

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

FDA Hearing : Cardiovascular Safety of ADHD Medications in Children & Adolescents M. Christopher Griffith, M.D. Clinical Assistant Professor: Emory University.
Complications of Deep Brain Stimulation: Risks of Placement vs Neurostimulator Device Issues Shahid M. Nimjee, MD, PhD Isaac O. Karikari, MD Tiffany R.
By Lisa Rosenberg Deep Brain Stimulation. Electrical probe implanted in brain Approved by FDA in mid 1990’s Hidden under skin Does not damage healthy.
Surgery For Parkinson’s Disease Current Practice and Future Directions
Epilepsy Surgery Matthew A. Howard III MD Professor and Chairman Department of Neurosurgery University of Iowa.
DEEP BRAIN STIMULATION: MOVING TOWARD A CLINICALLY EFFICIENT AND AVAILABLE THERAPY Peter Konrad, MD PhD Director, Functional Neurosurgery Vanderbilt University.
Deep Brain Stimulation Mark Anil Mansingh Simon Putzenlechner Philipp Bartner.
Electrical stimulation of the brain: Deep Brain Stimulation (DBS)
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Deep Brain Stimulation For parkinson’s disease
TECHNOLOGY IN REHABILITATION
Deep Brain Stimulation: Brain Pacemakers Kaitlin Abbate.
Aaron Mulheren, Kathryn Wilson, MSN, APN, Milind Deogaonkar, MD
U.S. Neurostimulation Markets Leveraging CRM Technology for Treating Neurological Conditions “Until recently, the only modes of treatment for many neurological.
CBR-1 Benefit/Risk Assessment for Use of Clozaril in the Treatment of Emergent Suicidal Behavior John M. Kane, MD Chairman, Department of Psychiatry The.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
The Effects of Deep Brain Stimulation on the Motor Symptoms of Parkinson’s Disease Aaron Mulheren Kathryn Wilson, MSN, APN Milind Deogaonkar, MD Science.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 16Psychopharmacology.
NeuroPace RNS System Rachel McAteer BME 281.  Intro:  Used to treat medically refractory partial epilepsy  Refractory epilepsy:  Frequent severe seizures.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
To determine the effect changing threshold values has on SISCOM image data sets.  Threshold changes used did not increase the similarity of the 2-detector.
BRAIN PACEMAKERS Madison Moreau BME 281 September 26, 2012.
 Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
 Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
An Innovative Mental Health Center. Reasons for HOPE: Advances in Mental Health Care Presented by Paul E. Keck, Jr., M.D. President and Chief Executive.
The Emergence of Therapeutic Neurostimulation: Reducing Barriers to Innovation and Growth John Reppas MD- PhD Director of Public Policy American Society.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
The Placebo Response and Effect  Can be significant  30% or more in certain interventions  An individual’s overall disease manifestation and treatment.
SANTE: Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy Professor Ley Sander MD PhD FRCP.
. Introduction The effect of subthalamic nucleus (STN) deep brain stimulation (DBS) on postural balance is controversial. Variability of results may be.
Cognition Workshop Dr Jill Rasmussen Dr Amy Chappell.
PARKINSON’S DISEASE LUKE CARROLL & LAUREN DESROCHES.
Deep Brain Stimulation: A Proven Treatment for Movement Disorders
Main topics Who are we at EMA and what is our regulatory experience in Parkinson’s disease (PD) Initiatives available at EMA to stimulate and support.
Myotonic Dystrophy Research: What’s Next
Nervous System Disorders and Homeostatic Imbalances
Continuity of Care in the Garden State
Quantification of Dose with Neuromodulation Device
Impulse Control Disorders (ICD) and Parkinson Disease (PD)
Analysis of a New Method for Studying Placebo Effects
WORLD FEDERATION OF NEUROSCIENCE NURSES
DBP: SIMULATION OF DEEP BRAIN STIMULATION
Atrial Fibrillation: When Should You Consider Ablation?
Pediatric Psychology: An Overview
Resolving outcome disparities in depression for minority primary care patients with collaborative care management Kurt B. Angstman, MS MD Associate Professor.
Falon Fiorillo & Breeanna Fournier
Insights from the NCDR® STS/ACC TVT Registry.
Copyright © American Speech-Language-Hearing Association
Success of a repeated tined lead trial in a refractory OAB population
Relationships Between the Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease-Rating Scale and Measures of Executive Function David.
The Effects of Levodopa and Deep Brain Stimulation on Subthalamic Local Field Low-Frequency Oscillations in Parkinson's Disease Neurosignals 2013;21:89-98.
Parkinson’s disease.
Andres M. Lozano, Nir Lipsman  Neuron 
Spinrad/Psychology Antipsychotic Drugs.
Sertraline In this section we’ll discuss the most relevant aspects of sertraline.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
The Psychiatrist's Role in Tardive Dyskinesia
Supported in part by Arkansas Blue Cross and Blue Shield
The Psychiatrist's Role in Tardive Dyskinesia
Deep Brain Stimulation: What, When, Why, How
New Models of Care in Idiopathic Pulmonary Fibrosis
Conceptual diagram of dopaminergic system and disease and drug effects
Presentation transcript:

How and When to Consider DBS in the Older Patient Erwin B. Montgomery, Jr. MD The Dr. Sigmund Rosen Scholar and Professor of Neurology University of Alabama at Birmingham

July 1, 2013 Medical Director Greenville Neuromodulation Center Greenville Neuromodulation Scholar in Neuroscience and Philosophy Thiel College Greenville, PA

Disclaimers and Conflict of Interest Material grants from Medtronic Neuromodulation Inc. Consultant to Great Lakes Neurotechnology Consultant Greenville Neuromodulation Services Consultant FHC, Inc.

Experimental and Off-label Uses Off-label uses of FDA approved devices and experimental and investigational uses will be identified when discussed The role of the FDA is to regulate the interstate commerce in drugs and devices; not to regulate the practice of medicine

Deep Brain Stimulation (DBS) Implantation of chromic electrical stimulation electrodes in various targets in the brain for the relief of symptoms and disabilities in neurological and psychiatric disease

7

DBS The brain is basically an electrical device Processes information electronically Neurotransmitters (basis for pharmacology) are the messengers not the message Disease is misinformation

DBS Unparalleled accuracy and precision Spatial resolution on millimeters Temporal resolution on the order of milliseconds

DBS Indications in the Elderly The same as any age group Certain indications more common in elderly Primary affect of age is in the co-morbidities Benefit may not be a much Increased risks NO specific age limit

Figure 2 Predictors of effective bilateral subthalamic nucleus stimulation for PD. Charles, PD; Van Blercom, N; Krack, P; Lee, SL; MD, PhD; Xie, J; Besson, G; Benabid, A-L; MD, PhD; Pollak, P Neurology. 59(6):932-934, September 24, 2002. Figure 2 . Scatter plot and linear regression with 95% confidence interval shown with the R2 value, i.e., the percent of the variation in improvement from stimulation accounted for by age. Individual data points are represented as black squares (n = 54 patients). Data values were calculated as in figure 1. The correlation coefficient, r (Spearman's rho), is significant at the 0.01 level (two-tailed). ©2002 American Academy of Neurology. Published by LWW_American Academy of Neurology. 2

Issue of Pre-existing Cognitive Decline Concerns based on informed speculation It just makes sense that invading the brain is going to make cognitive function worse even if not known complication such as intra-cerebral hemorrhage or stroke Essentially untested Most exclude patients with cognitive decline so hypothesis not tested

DBS effects on Cognitive Function Only demonstrated consistent decline is in verbal fluency which is mild to moderate in severity Liberalization of cognitive requirements

DBS in Parkinson’s Disease More effective and less long-term side effects than best medical therapy 2-3% risk of severe or permanent adverse effect Intra-cerebral hemorrhage Infection Rare complications Seizures Hardware failure

DBS in Parkinson’s Disease Candidate criteria Idiopathic Parkinson’s disease Issue of atypical parkinsonism Exhausted reasonable attempts at medication therapy Parkinson related disability is the “rate limiting” condition, not cognition Able to tolerate surgery

Exhausted Reasonable Attempts at Medication Therapy Very problematic Thousands of potential combinations Think in terms of drug class rather than individual agents Dopamine agonists Is issue lack of efficacy or side effect Agents within class relatively the same efficacy Special case in extended or long acting agents differ in side effects

Current and Future Indications FDA approved Parkinson’s disease Essential tremor Dystonia Obsessive-compulsive disorder Off-label uses Hemiballismus Chorea Tardive dyskinesia Tardive dystonia Cerebellar outflow tremor Hyperkinetic disorders Experimental or investigational Alzheimer's disease Epilepsy Depression Stroke

Role of the Gerontologist, Internist, Family Practitioner Team Patient referred for evaluation not DBS surgery Refer to Movement Disorders/DBS expert not surgeon Major selection criteria is medical not surgical Low threshold Movement Disorders/DBS expert = high threshold

Questions?